Investigation of platelet apoptosis in adult patients with chronic immune thrombocytopenia. 2017

Gang Deng, and Shifang Yu, and Qiming Li, and Yunlei He, and Wei Liang, and Lu Yu, and Deyi Xu, and Tao Sun, and Ri Zhang, and Qiang Li
a The Ningbo Central Blood Station , Ningbo , China.

OBJECTIVE Immune thrombocytopenia (ITP) is an acquired and heterogeneous autoimmune-mediated hematological disease typically characterized by a low platelet count. Emerging evidence over the past several years suggests that platelet biogenesis and ageing are regulated, at least in part, by apoptotic mechanisms. However, the association between decreased platelets and apoptosis in ITP patients is poorly understood. To better understand the role of platelet apoptosis in ITP pathophysiology, we investigated apoptotic markers in platelets acquired from 40 chronic ITP patients. Furthermore, the results of ITP patients were compared to those from 40 healthy individuals. METHODS Markers of apoptosis, including phosphatidylserine (PS) exposure and mitochondrial inner membrane potentials (ΔΨm), were examined using flow cytometry. The expression of pro-apoptotic molecules such as Bak and Bax and anti-apoptotic molecules such as Bcl-xL were determined using quantitative real-time PCR (qRT-PCR) and Western blotting. RESULTS Our study demonstrated that the platelet mitochondrial membrane depolarization in chronic ITP patients tended to be higher than in healthy controls. Additionally, the proportion of platelets with surface-exposed PS in chronic ITP was significantly higher than that of controls. The results showed that the expression levels of Bak and Bax were significantly higher in chronic ITP patients than in healthy controls; Bcl-xL expression levels were significantly decreased in the platelets of chronic ITP patients compared to healthy controls. CONCLUSIONS study indicates that the enhancement of platelet apoptosis observed in patients with chronic ITP may be one of the pathogenic mechanisms of chronic ITP.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010976 Platelet Count The number of PLATELETS per unit volume in a sample of venous BLOOD. Blood Platelet Count,Blood Platelet Number,Platelet Number,Blood Platelet Counts,Blood Platelet Numbers,Count, Blood Platelet,Count, Platelet,Counts, Blood Platelet,Counts, Platelet,Number, Blood Platelet,Number, Platelet,Numbers, Blood Platelet,Numbers, Platelet,Platelet Count, Blood,Platelet Counts,Platelet Counts, Blood,Platelet Number, Blood,Platelet Numbers,Platelet Numbers, Blood
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D005260 Female Females
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

Gang Deng, and Shifang Yu, and Qiming Li, and Yunlei He, and Wei Liang, and Lu Yu, and Deyi Xu, and Tao Sun, and Ri Zhang, and Qiang Li
October 2019, British journal of haematology,
Gang Deng, and Shifang Yu, and Qiming Li, and Yunlei He, and Wei Liang, and Lu Yu, and Deyi Xu, and Tao Sun, and Ri Zhang, and Qiang Li
November 2020, Expert review of hematology,
Gang Deng, and Shifang Yu, and Qiming Li, and Yunlei He, and Wei Liang, and Lu Yu, and Deyi Xu, and Tao Sun, and Ri Zhang, and Qiang Li
December 2020, Hematology (Amsterdam, Netherlands),
Gang Deng, and Shifang Yu, and Qiming Li, and Yunlei He, and Wei Liang, and Lu Yu, and Deyi Xu, and Tao Sun, and Ri Zhang, and Qiang Li
June 2012, Thrombosis and haemostasis,
Gang Deng, and Shifang Yu, and Qiming Li, and Yunlei He, and Wei Liang, and Lu Yu, and Deyi Xu, and Tao Sun, and Ri Zhang, and Qiang Li
August 2015, British journal of haematology,
Gang Deng, and Shifang Yu, and Qiming Li, and Yunlei He, and Wei Liang, and Lu Yu, and Deyi Xu, and Tao Sun, and Ri Zhang, and Qiang Li
July 2018, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Gang Deng, and Shifang Yu, and Qiming Li, and Yunlei He, and Wei Liang, and Lu Yu, and Deyi Xu, and Tao Sun, and Ri Zhang, and Qiang Li
December 2009, Hematology/oncology clinics of North America,
Gang Deng, and Shifang Yu, and Qiming Li, and Yunlei He, and Wei Liang, and Lu Yu, and Deyi Xu, and Tao Sun, and Ri Zhang, and Qiang Li
October 2012, Therapeutic advances in hematology,
Gang Deng, and Shifang Yu, and Qiming Li, and Yunlei He, and Wei Liang, and Lu Yu, and Deyi Xu, and Tao Sun, and Ri Zhang, and Qiang Li
January 2016, PloS one,
Gang Deng, and Shifang Yu, and Qiming Li, and Yunlei He, and Wei Liang, and Lu Yu, and Deyi Xu, and Tao Sun, and Ri Zhang, and Qiang Li
January 2015, Scandinavian journal of clinical and laboratory investigation,
Copied contents to your clipboard!